First Trust Advisors LP raised its position in Davita Inc (NYSE:DVA) by 5.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 650,039 shares of the company’s stock after purchasing an additional 31,743 shares during the quarter. First Trust Advisors LP’s holdings in Davita were worth $46,965,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in DVA. Schroder Investment Management Group grew its stake in Davita by 769.0% in the third quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock valued at $25,387,000 after acquiring an additional 384,224 shares during the period. Locust Wood Capital Advisers LLC acquired a new stake in Davita in the fourth quarter valued at approximately $20,657,000. Canada Pension Plan Investment Board grew its stake in Davita by 14.7% in the third quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock valued at $26,390,000 after acquiring an additional 56,988 shares during the period. Teacher Retirement System of Texas acquired a new stake in Davita in the fourth quarter valued at approximately $3,043,000. Finally, Speece Thorson Capital Group Inc. grew its stake in Davita by 14.5% in the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after acquiring an additional 40,667 shares during the period. 84.45% of the stock is owned by hedge funds and other institutional investors.
Davita Inc (NYSE DVA) opened at $73.65 on Friday. The stock has a market capitalization of $13,438.33, a P/E ratio of 21.41, a P/E/G ratio of 1.65 and a beta of 0.99. The company has a current ratio of 2.88, a quick ratio of 1.35 and a debt-to-equity ratio of 1.87. Davita Inc has a 1 year low of $52.51 and a 1 year high of $80.71.
Davita (NYSE:DVA) last announced its earnings results on Tuesday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.02). The company had revenue of $2.78 billion for the quarter, compared to analysts’ expectations of $3.90 billion. Davita had a net margin of 4.65% and a return on equity of 12.86%. During the same period in the previous year, the firm earned $0.98 EPS. research analysts forecast that Davita Inc will post 4.18 EPS for the current year.
In related news, CEO Javier Rodriguez sold 22,532 shares of Davita stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $67.48, for a total transaction of $1,520,459.36. Following the transaction, the chief executive officer now owns 210,317 shares of the company’s stock, valued at $14,192,191.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Charles Berg sold 7,048 shares of Davita stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $69.24, for a total value of $488,003.52. Following the transaction, the insider now directly owns 5,359 shares in the company, valued at approximately $371,057.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 121,509 shares of company stock worth $8,310,388. 2.10% of the stock is owned by insiders.
A number of equities research analysts have commented on the company. Bank of America reissued a “buy” rating and issued a $92.00 price objective (up previously from $85.00) on shares of Davita in a research note on Thursday, January 11th. Wolfe Research raised Davita from a “market perform” rating to an “outperform” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. raised their price objective on Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 7th. SunTrust Banks reissued a “hold” rating and issued a $80.00 price objective on shares of Davita in a research note on Wednesday. Finally, Robert W. Baird raised Davita from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $63.00 to $82.00 in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. Davita has an average rating of “Hold” and a consensus price target of $79.30.
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.